EMEA-002106-PIP01-16-M02
Key facts
| Active substance |
Leriglitazone
|
| Therapeutic area |
Neurology
|
| Decision number |
P/0115/2022
|
| PIP number |
EMEA-002106-PIP01-16-M02
|
| Pharmaceutical form(s) |
Oral suspension
|
| Condition(s) / indication(s) |
Treatment of adrenoleukodystrophy
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
Minoryx Therapeutics S.L.
Tel. ++34 935441466 |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|